@article{2523c2d8599f461897091d918ff1b632,
title = "Prevalence of pharmacogenomic variants affecting the efficacy of clopidogrel therapy in the Hispanic Community Health Study/Study of Latinos cohort",
abstract = "Purpose: Although clopidogrel is the most widely used oral P2Y12 receptor antagonist, up to 10% of acute coronary syndrome patients treated with clopidogrel will experience a recurrent myocardial infarction and 2-3% will experience stent thrombosis within 1 year. The purpose of this research is to describe the prevalence of pharmacogene variants associated with clopidogrel responsiveness (CYP2C19, B4GALT2, ABCB1, PON1, CES1 and P2RY12) in Hispanic/Latino patients of diverse backgrounds. Methods: Minor allele frequencies of nine variants from participants of Hispanic Community Health Study/Study of Latinos were compared between subpopulations as well as to continental ancestry references using z-test for independent proportions. Results: MAFs for six out of nine variants differed between Caribbean and Mainland subpopulations (p < 0.05). Compared with European reference group, MAFs of ABCB1, CES1 and PON1 were higher in Hispanic Community Health Study/Study of Latinos, whereas B4GALT2 and CYP2C19∗2 and ∗17 were lower. Conclusion: Significant differences in the prevalence of most pharmacogenomic variants related to clopidogrel response provide a foundation to better inform ongoing and future clinical studies of clopidogrel pharmacogenetics in the US Hispanic/Latino populations.",
keywords = "ABCB1, B4GALT2, CES1, CYP2C19, Hispanic, Latino, P2RY12, PON1, clopidogrel, pharmacogenes",
author = "Kyle Melin and Moon, {Jee Young} and Qibin Qi and Hernandez-Suarez, {Dagmar F.} and Jorge Duconge and Simin Hua and Sara Gonzalez and Donglin Zeng and Kaplan, {Robert C.}",
note = "Funding Information: The Hispanic Community Health Study/Study of Latinos is a collaborative study supported by contracts from the National Heart, Lung and Blood Institute (NHLBI) to the University of North Carolina (HHSN268201300001I/N01-HC-65233), University of Miami (HHSN268201300004I/N01-HC-65234), Albert Einstein College of Medicine (HHSN268201300002I/N01-HC-65235), University of Illinois at Chicago – HHSN268201300003I/N01-HC-65236 Northwestern Univ) and San Diego State University (HHSN268201300005I/ N01-HC-65237). The following Institutes/Centers/Offices have contributed to the HCHS/SOL through a transfer of funds to the NHLBI: National Institute on Minority Health and Health Disparities, National Institute on Deafness and Other Communication Disorders, National Institute of Dental and Craniofacial Research, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Neurological Disorders and Stroke, NIH Institution-Office of Dietary Supplements. This project was also partially supported by The National Institute of Health Award Numbers: HCTRECD R25MD007607 and HiREC S21MD001830 from the National Institute on Minority Health and Health Disparities. No writing assistance was utilized in theproduction of this manuscript. Publisher Copyright: {\textcopyright} 2018 2018 Future Medicine Ltd.",
year = "2019",
month = jan,
doi = "10.2217/pgs-2018-0148",
language = "English (US)",
volume = "20",
pages = "75--83",
journal = "Pharmacogenomics",
issn = "1462-2416",
publisher = "Future Medicine Ltd.",
number = "2",
}